Common Side Effects of Pemetrexed in Older Adult Smokers with NSCLC or Mesothelioma
Pemetrexed causes primarily hematologic toxicity in elderly patients, with grade 3/4 neutropenia (33-52%), thrombocytopenia (13-29%), and anemia (19%), along with fatigue (10-56%), nausea (52-56%), and gastrointestinal symptoms as the most common adverse effects. 1, 2
Hematologic Toxicity (Most Common)
The predominant toxicities are blood-related and occur more frequently in elderly patients:
- Neutropenia: Grade 3/4 neutropenia occurs in 33-52% of elderly patients, which is significantly higher than younger patients (22%) 2, 3
- Thrombocytopenia: Grade 3/4 occurs in 13-29% of elderly patients versus 6% in younger patients 2, 3
- Anemia: Grade 3/4 anemia affects 19% of elderly patients 3
- Febrile neutropenia: Occurs in approximately 4.5-4.8% of patients regardless of age 4, 2
Important caveat: When pemetrexed is combined with carboplatin (common in elderly patients), grade 3/4 neutropenia increases to 36.1% compared to 23.9% with cisplatin 5
Non-Hematologic Toxicity
Gastrointestinal Effects
- Nausea: Occurs in 52-56% of patients (grade 3-4 in 3.5%) 1
- Constipation: Affects 35% of patients 1
- Diarrhea: Occurs in 31% (grade 3-4 in 2-3%) 1
- Vomiting: Affects 24% of patients 1
- Anorexia/decreased appetite: Occurs in 28-30% 1
Constitutional Symptoms
- Fatigue/asthenia: The most common non-hematologic toxicity, occurring in 56% of patients (grade 3-4 in 10-16%) 1, 3
- Pyrexia: Affects 20% of patients 1
Other Notable Toxicities
- Rash: Occurs in 25% of patients (grade 3-4 in 2%) 1
- Cough and dyspnea: Each affects approximately 21-28% of patients 1
Critical Safety Concerns
Renal Toxicity
- Acute kidney injury is a leading cause of pemetrexed discontinuation (3% of patients) 1
- Increased risk with NSAIDs: In patients with creatinine clearance 45-79 mL/min, avoid ibuprofen for 2 days before, day of, and 2 days after pemetrexed administration due to increased drug exposure and toxicity risk 1
Pulmonary Toxicity
- Pneumonitis: Occurs in approximately 2% of patients and is a common reason for discontinuation 1
- Interstitial lung disease: Can occur, particularly in elderly patients (grade 3+ in rare cases) 5, 1
Severe Skin Reactions
- Bullous and exfoliative skin toxicity can occur, requiring permanent discontinuation 1
- Radiation recall: Can develop in patients who received prior radiation therapy 1
Special Considerations for Elderly Smokers
Critical point: Pemetrexed should NOT be used in patients with squamous cell histology, which is more common in smokers 5
- Elderly patients (≥70 years) experience more frequent hematologic toxicity compared to younger patients, particularly when combined with carboplatin 5
- Treatment-related deaths have been observed in elderly patients, particularly with multi-drug combinations 5
- Despite increased toxicity, efficacy outcomes (response rates, progression-free survival, overall survival) are similar between elderly and younger patients 5, 2
Toxicity Mitigation
Mandatory supplementation: All patients must receive vitamin B12 and folic acid supplementation to significantly reduce toxicity incidence and severity without compromising efficacy 1, 4, 6
Common pitfall: Failure to provide vitamin supplementation dramatically increases toxicity rates and should never be omitted 6